KAPA
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.06 | $0 | -$1M |
| 2026 Q1 | -0.08 | $0 | -$1M |
| 2025 Q4 | -0.07 | $0 | -$1M |
| 2025 Q3 | -0.07 | $0 | -$838,000 |
| 2025 Q2 | -0.08 | $0 | -$805,000 |
| 2025 Q1 | -0.08 | $0 | -$714,000 |
| 2024 Q4 |
| -0.07 |
| $0 |
| -$2M |
| 2024 Q3 | -0.10 | $0 | -$2M |